{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,3,5]],"date-time":"2026-03-05T23:50:58Z","timestamp":1772754658835,"version":"3.50.1"},"reference-count":44,"publisher":"Wiley","issue":"5","license":[{"start":{"date-parts":[[2008,4,21]],"date-time":"2008-04-21T00:00:00Z","timestamp":1208736000000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/onlinelibrary.wiley.com\/termsAndConditions#vor"}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["Human Psychopharmacology"],"published-print":{"date-parts":[[2008,7]]},"abstract":"<jats:title>Abstract<\/jats:title><jats:sec><jats:title>Aims<\/jats:title><jats:p>Patients with dual diagnosis are often excluded from clinical trials although more than half of all individuals with Bipolar Disorder have a substance abuse problem at some point in their lifetime, representing a high\u2010risk clinical population. The purpose of this study was to investigate the safety and efficacy of quetiapine in the treatment of alcohol dependence comorbid with disorders characterized by high levels of mood and behavioral instability.<\/jats:p><\/jats:sec><jats:sec><jats:title>Methods<\/jats:title><jats:p>Twenty\u2010eight subjects, after a detoxification period, were orally treated with flexible doses of quetiapine for 16 weeks. At each assessment patients were evaluated through the Obsessive Compulsive Drinking Scale (OCDS), the Visual Analogue Scale (VAS) for craving, the Clinical Institute Withdrawal Assessment for Alcohol (CIWA\u2010Ar), the Brief Psychiatric Rating Scale (BPRS), the Hamilton Depression Rating Scale (HDRS), the Young Mania Rating Scale (YMRS), and the Clinical Global Impression (CGI) scale.<\/jats:p><\/jats:sec><jats:sec><jats:title>Results<\/jats:title><jats:p>Forty\u2010three percent of patients remained totally alcohol free, 32% patients relapsed, with an average of 15.4 drinking days in the period of the study (112 days) and 25% dropped\u2010out. Significant reductions from baseline to exit were observed in the OCDS, VAS, BPRS, HDRS, and number of drinking days per week. Changes in alcohol craving correlated with psychiatric symptoms as to BPRS and HDRS, with the highest level of correlation evidenced for the HDRS items of insomnia.<\/jats:p><\/jats:sec><jats:sec><jats:title>Discussion<\/jats:title><jats:p>In this open\u2010label study, quetiapine decreased alcohol consumption, craving for alcohol, and psychiatric symptoms intensity, maintaining a good level of tolerance. A strength of this study is that the use of quetiapine was not adjunctive with other pharmacological and non\u2010pharmacological treatment. Double\u2010blind placebo\u2010controlled studies are required with a larger study population to confirm these data. In the meantime, for a select group of psychiatric patients, quetiapine may offer some advantages in preventing relapse. Copyright \u00a9 2008 John Wiley &amp; Sons, Ltd.<\/jats:p><\/jats:sec>","DOI":"10.1002\/hup.944","type":"journal-article","created":{"date-parts":[[2008,4,21]],"date-time":"2008-04-21T13:27:29Z","timestamp":1208784449000},"page":"417-424","source":"Crossref","is-referenced-by-count":64,"title":["Quetiapine decreases alcohol consumption, craving, and psychiatric symptoms in dually diagnosed alcoholics"],"prefix":"10.1002","volume":"23","author":[{"given":"G.","family":"Martinotti","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"S.","family":"Andreoli","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"M.","family":"Di Nicola","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"M.","family":"Di Giannantonio","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"M.","family":"Sarchiapone","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"L.","family":"Janiri","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"311","published-online":{"date-parts":[[2008,4,21]]},"reference":[{"issue":"1","key":"e_1_2_1_2_1","first-page":"177","article-title":"Substance abuse as a risk factor for tardive dyskinesia: a retrospective analysis of 1,027 patients","volume":"33","author":"Bailey LG","year":"1997","journal-title":"Psychopharmacol Bull"},{"key":"e_1_2_1_3_1","doi-asserted-by":"publisher","DOI":"10.4088\/JCP.v67n0705"},{"key":"e_1_2_1_4_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.pnpbp.2005.06.010"},{"key":"e_1_2_1_5_1","doi-asserted-by":"publisher","DOI":"10.1093\/schbul\/16.1.81"},{"key":"e_1_2_1_6_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.psc.2005.01.004"},{"key":"e_1_2_1_7_1","doi-asserted-by":"publisher","DOI":"10.1176\/appi.ajp.162.7.1351"},{"issue":"7","key":"e_1_2_1_8_1","first-page":"331","article-title":"A double blind study with melperone and placebo in the treatment of chronic alcoholics","volume":"16","author":"Carlsson C","year":"1978","journal-title":"Int J Clin Pharmacol Biopharm"},{"key":"e_1_2_1_9_1","doi-asserted-by":"publisher","DOI":"10.1034\/j.1399-5618.2001.30403.x"},{"key":"e_1_2_1_10_1","doi-asserted-by":"publisher","DOI":"10.1034\/j.1399-5618.2000.020306.x"},{"key":"e_1_2_1_11_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.eurpsy.2006.04.007"},{"key":"e_1_2_1_12_1","doi-asserted-by":"publisher","DOI":"10.1093\/oxfordjournals.schbul.a033464"},{"key":"e_1_2_1_13_1","doi-asserted-by":"publisher","DOI":"10.1111\/j.1530-0277.1999.tb04223.x"},{"key":"e_1_2_1_14_1","doi-asserted-by":"publisher","DOI":"10.3109\/10673229909017206"},{"issue":"2","key":"e_1_2_1_15_1","first-page":"121","article-title":"Clopentixol decanoate in the treatment of chronic alcoholism","volume":"81","author":"Hochenegg L","year":"1981","journal-title":"Acta Psychiatr Belg"},{"key":"e_1_2_1_16_1","unstructured":"Istituto Nazionale di Statistica (ISTAT).2006. L'uso e l'abuso di alcol in Italia. April available at:www.istat.it\/salastampa\/ comunicati"},{"key":"e_1_2_1_17_1","doi-asserted-by":"publisher","DOI":"10.1097\/JCP.0b013e3180ca86e5"},{"key":"e_1_2_1_18_1","doi-asserted-by":"publisher","DOI":"10.1001\/archpsyc.57.6.553"},{"key":"e_1_2_1_19_1","doi-asserted-by":"publisher","DOI":"10.1176\/ajp.142.11.1259"},{"key":"e_1_2_1_20_1","doi-asserted-by":"publisher","DOI":"10.1186\/1471-244X-6-44"},{"key":"e_1_2_1_21_1","doi-asserted-by":"publisher","DOI":"10.2165\/00023210-200115050-00006"},{"key":"e_1_2_1_22_1","doi-asserted-by":"publisher","DOI":"10.1093\/alcalc\/33.6.563"},{"key":"e_1_2_1_23_1","doi-asserted-by":"publisher","DOI":"10.1016\/S0740-5472(01)00205-7"},{"key":"e_1_2_1_24_1","doi-asserted-by":"publisher","DOI":"10.1097\/01.jcp.0000106230.36344.b1"},{"key":"e_1_2_1_25_1","doi-asserted-by":"publisher","DOI":"10.1111\/j.1399-5618.2006.00283.x"},{"key":"e_1_2_1_26_1","doi-asserted-by":"publisher","DOI":"10.1111\/j.1399-5618.2005.00208.x"},{"key":"e_1_2_1_27_1","doi-asserted-by":"publisher","DOI":"10.1016\/0740-5472(92)90062-S"},{"key":"e_1_2_1_28_1","doi-asserted-by":"publisher","DOI":"10.1097\/01.jcp.0000138763.23482.2a"},{"key":"e_1_2_1_29_1","doi-asserted-by":"publisher","DOI":"10.15288\/jsa.1986.47.196"},{"issue":"13","key":"e_1_2_1_30_1","first-page":"12","article-title":"Efficacy, safety, and tolerability of quetiapine in patients with schizophrenia","volume":"63","author":"Nasrallah HA","year":"2002","journal-title":"J Clin Psychiatry"},{"issue":"13","key":"e_1_2_1_31_1","first-page":"5","article-title":"Quetiapine: preclinical studies, pharmacokinetics, drug interactions, and dosing","volume":"63","author":"Nemeroff CB","year":"2002","journal-title":"J Clin Psychiatry"},{"key":"e_1_2_1_32_1","doi-asserted-by":"publisher","DOI":"10.1001\/archpsyc.1973.04200020052006"},{"key":"e_1_2_1_33_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.pnpbp.2006.08.012"},{"issue":"6","key":"e_1_2_1_34_1","first-page":"452","article-title":"Potential benefits of quetiapine in the treatment of substance dependence disorders","volume":"29","author":"Sattar SP","year":"2004","journal-title":"J Psychiatry Neurosci"},{"key":"e_1_2_1_35_1","doi-asserted-by":"publisher","DOI":"10.1093\/schbul\/16.1.111"},{"key":"e_1_2_1_36_1","doi-asserted-by":"publisher","DOI":"10.3109\/00952998108999127"},{"key":"e_1_2_1_37_1","doi-asserted-by":"publisher","DOI":"10.1016\/S0010-440X(98)90058-X"},{"key":"e_1_2_1_38_1","doi-asserted-by":"publisher","DOI":"10.1007\/s00213-002-1016-3"},{"issue":"7","key":"e_1_2_1_39_1","doi-asserted-by":"crossref","first-page":"1119","DOI":"10.1176\/ajp.156.7.1119a","article-title":"Clozapine for substance\u2010abusing schizophrenic patients","volume":"156","author":"Tsuang JW","year":"1999","journal-title":"Am J Psychiatry"},{"key":"e_1_2_1_40_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.pnpbp.2004.06.022"},{"key":"e_1_2_1_41_1","first-page":"105","volume-title":"Personality Disorders: Current Research and Treatments","author":"Vaglum P","year":"2005"},{"key":"e_1_2_1_42_1","doi-asserted-by":"publisher","DOI":"10.1034\/j.1399-5618.2002.01204.x"},{"key":"e_1_2_1_43_1","doi-asserted-by":"publisher","DOI":"10.1159\/000054017"},{"key":"e_1_2_1_44_1","doi-asserted-by":"publisher","DOI":"10.1176\/appi.ajp.161.11.2108"},{"key":"e_1_2_1_45_1","doi-asserted-by":"publisher","DOI":"10.1097\/00004714-200002000-00016"}],"container-title":["Human Psychopharmacology: Clinical and Experimental"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.wiley.com\/onlinelibrary\/tdm\/v1\/articles\/10.1002%2Fhup.944","content-type":"unspecified","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/onlinelibrary.wiley.com\/doi\/pdf\/10.1002\/hup.944","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2023,11,14]],"date-time":"2023-11-14T11:42:25Z","timestamp":1699962145000},"score":1,"resource":{"primary":{"URL":"https:\/\/onlinelibrary.wiley.com\/doi\/10.1002\/hup.944"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2008,4,21]]},"references-count":44,"journal-issue":{"issue":"5","published-print":{"date-parts":[[2008,7]]}},"alternative-id":["10.1002\/hup.944"],"URL":"https:\/\/doi.org\/10.1002\/hup.944","archive":["Portico"],"relation":{},"ISSN":["0885-6222","1099-1077"],"issn-type":[{"value":"0885-6222","type":"print"},{"value":"1099-1077","type":"electronic"}],"subject":[],"published":{"date-parts":[[2008,4,21]]}}}